Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 103Recruiting 59Unknown 53Terminated 19Not yet recruiting 18Active not recruiting 12Withdrawn 9Suspended 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 29Magnetic Resonance Spectroscopy 18Biopsy 16Cyclophosphamide 15Nivolumab 10Paclitaxel 9Vincristine 8Cisplatin 8venetoclax 7Prednisone 7Gemcitabine 7Doxorubicin 7Bevacizumab 7Azacitidine 7pembrolizumab 6Radiotherapy 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Rituximab 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Injections 5Everolimus 5Capecitabine 5fludarabine phosphate 4Taxes 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Interventional × Folfox protocol × Clear all
NCT05033522 2025-10-23

ALIVE

Mirror Biologics, Inc.

Phase 2/3 Suspended
150 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡